Compare Amylx Pharmaceuticals Inc (AMLX) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Petróleo Brasileiro SA — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Petróleo Brasileiro SA trades at $18 (market cap $114.31B). The key difference: Petróleo Brasileiro SA is far larger — about 45.2× Amylx Pharmaceuticals Inc's market cap, and Petróleo Brasileiro SA pays a 9.62% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | PBR | |
|---|---|---|
Market Cap | $2.53B | $114.31B |
Sector | Health | Technology |
52-Week High | $24.19 | $22.03 |
52-Week Low | $7.82 | $11.54 |
Enterprise Value | $2.28B | $174.73B |
Dividend Yield | — | 9.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
PBR trades at $17.96, down 3.02% today, with bearish technical signals but strong fundamentals. The company reported robust Q2 2026 results with record production of 3.34 million boe/day and net earnings surging 120% year-over-year. Valuation metrics remain attractive with P/E of 4.63 and ROE of 30.77%. Analyst consensus is bullish with 11 buy ratings out of 22 total coverage.
PBR presents a compelling value opportunity with strong profitability and dividend yield, though regulatory uncertainty and oil price volatility pose risks. The company's production growth trajectory and cost-efficient pre-salt assets support long-term upside potential despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
